Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?

Netherlands Heart Journal

Volumn 19, Issue 6, 2011, Pages 279-284

  Breet, N J ^a,b   van Donkersgoed, H E ^b   van Werkum, J W ^a,b   Bouman, H J ^a,b   Kelder, J C ^a,b   Zijlstra, F ^c   Hackeng, C M ^a   ten Berg, J M ^a,b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b St Antonius Center for Platelet Function Research   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Clopidogrel; Platelet reactivity

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COUMARIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR; THIENOPYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD VESSEL REACTIVITY; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY STENT; FEMALE; GERIATRIC PATIENT; HUMAN; LOADING DRUG DOSE; LOW BODY WEIGHT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; POPULATION RESEARCH; PREDICTION; PROSPECTIVE STUDY; RISK ASSESSMENT; STROKE; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK;

EID: 79961162495     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-011-0105-5     Document Type: Article

References (24)

1. Steinhubl SR, Berger PB, Mann III JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20.
2. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-33.
3. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison between platelet function tests in predicting clinical outcome in patients undergoing coronary stent placement. JAMA. 2010;303:754-62.
4. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-5.
5. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Card. 2005;46:1820-6.
6. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12- month follow-up. Circulation. 2009;119:237-42.
7. Geisler T, Langer H, Wydymus M, et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J. 2006;27:2420-5.
8. Combescure C, Fontana P, Mallouk N, et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2010;8:923-33.
9. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.
10. Mokhtar OA, Lemesle G, Armero S, et al. Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thromb Res. 2010;126:e147-9.
11. Bonello L, De Labriolle A, Scheinowitz M, et al. Emergence of the concept of platelet reactivity monitoring of response to thienopyridines. Heart. 2009;95:1214-9.
12. van Werkum JW, Harmsze AM, Elsenberg EH, et al. The use of the VerifyNow system to monitor antiplatelet therapy: a review of the current evidence. Platelets. 2008;19:479-88.
13. van Werkum JW, Hackeng CM, Smit JJ, et al. Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiol. 2008;8:33-55.
14. Paracelsus WP. An Introduction to Philosophical. In: Medicine in the Era of the Renaissance. Basel: Karger; 1982.
15. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-30.
16. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-76.
17. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med. 2007;357:2078-81.
18. Sibbing D, Schulz S, Braun S, et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost. 2010;8:250-6.
19. Sibbing D, Steinhubl SR, Schulz S, et al. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogreltreated patients: initial evidence of a therapeutic window. J Am Coll Cardiol. 2010;56:317-8.
20. Cuisset T, Cayla G, Frere C, et al. Predictive value of posttreatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? Euro- Intervention. 2009;5:325-9.
21. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-33.
22. Small DS, Li YG, Ernest CS, et al. Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent. J Clin Pharmacol. 2010;51:321-32.
23. Wiviott SD, Antman EM, Prasugrel BE. Prasugrel. Circulation. 2010;122:394-403.
24. Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol. 2006;60:144-51.